1. Park, S.J., et al, Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol, 2014. 20(33): p. 11525-37.
2. Baumgart, D.C. and S.R. Carding, Inflammatory bowel disease: cause and immunobiology. Lancet, 2007. 369(9573): p. 1627-40.
3. 「難治性炎症性腸管障害に関する調査研究」(鈴木班),潰瘍性大腸炎・クローン病 診断基準・治療指針.令和元年度分担研究報告書,2020: p. 5-19
4. Truelove, S.C. and L.J. Witts, Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J, 1955. 2(4947): p. 1041-8.
5. Ogata, H., et al., A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut, 2006. 55(9): p. 1255-62.
6. Rutgeerts, P., et al., Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2005. 353(23): p. 2462-76.
7. Sandborn, W.J., et al., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 2012. 142(2): p. 257-65 e1-3.
8. Sandborn, W.J., et al., Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 2014. 146(1): p. 96-109 e1.
9. Sandborn, W.J., et al., Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 2017. 376(18): p. 1723-36.
10. Feagan, B.G., et al., Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013. 369(8): p. 699-710.
11. Endo, K., et al., A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract, 2016. 2016: p. 3162595.
12. Mao, E.J., et al., Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther, 2017. 45(1): p. 3-13.
13. Rodriguez-Lago, I., et al., Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther, 2020. 51(9): p. 870-9.
14. Rungoe, C., et al., Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut, 2014. 63(10): p. 1607-16.
15. Biondi, A., et al., Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol, 2012. 18(16): p. 1861-70.
16. Rizzo, G., et al., Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol, 2014. 20(17): p. 4839-45.
17. Jostins, L., et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012. 491(7422): p. 119-24.
18. Liu, J.Z., et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet, 2015. 47(9): p. 979-86.
19. Kawai, Y., et al., Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet, 2015. 60(10): p. 581-7.
20. Okamoto, D., et al., Genetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array. Inflamm Bowel Dis, 2020. 26(8): p. 1177-87.
21. Shiga, H., et al., What determines the later clinical course of patients who do not undergo colectomy at the first attack? A Japanese cohort study on ulcerative colitis. Digestion, 2010. 81(2): p. 104-12.
22. Sicilia, B., et al., [Ulcerative pancolitis predicts the need for colectomy: study of an incident cohort of patients with ulcerative colitis in Aragon (Spain)]. Gastroenterol Hepatol, 2005. 28(2): p. 55-9.
23. Vulliemoz, M., et al., TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion, 2020. 101 Suppl 1: p. 16-26.
24. Uchino, M., et al., Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surg Today, 2019. 49(12): p. 1066-73.
25. Argollo, M.C., et al., The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol, 2018. 32-33: p. 79-87.
26. Singh, S., et al., AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019. 156(3): p. 769-808 e29.
27. Okada, Y., et al., HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn's disease. Gastroenterology, 2011. 141(3): p. 864-71 e1-5.
28. Aizawa, H., et al., HLA-B is the best candidate of susceptibility genes in HLA for Japanese ulcerative colitis. Tissue Antigens, 2009. 73(6): p. 569-74.
29. Abelson, J.S., et al., Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. Ann Surg, 2018. 268(2): p. 311-7.
30. Andrew, R.E. and E. Messaris, Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg, 2016. 8(9): p. 598-605.